151 related articles for article (PubMed ID: 35930611)
1. Hepatitis E virus infection in the United States: Seroprevalence, risk factors and the influence of immunological assays.
Pisano MB; Campbell C; Anugwom C; Ré VE; Debes JD
PLoS One; 2022; 17(8):e0272809. PubMed ID: 35930611
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis E seroprevalence in the United States: Results for immunoglobulins IGG and IGM.
Cangin C; Focht B; Harris R; Strunk JA
J Med Virol; 2019 Jan; 91(1):124-131. PubMed ID: 30168589
[TBL] [Abstract][Full Text] [Related]
3. Performance evaluation of five commercial assays in assessing seroprevalence of HEV antibodies among blood donors.
Al-Absi ES; Al-Sadeq DW; Younis MH; Yassine HM; Abdalla OM; Mesleh AG; Hadwan TA; Amimo JO; Thalib L; Nasrallah GK
J Med Microbiol; 2018 Sep; 67(9):1302-1309. PubMed ID: 30051802
[TBL] [Abstract][Full Text] [Related]
4. Decline in hepatitis E virus antibody prevalence in the United States from 1988-1994 to 2009-2010.
Teshale EH; Denniston MM; Drobeniuc J; Kamili S; Teo CG; Holmberg SD
J Infect Dis; 2015 Feb; 211(3):366-73. PubMed ID: 25147277
[TBL] [Abstract][Full Text] [Related]
5. Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey.
Ditah I; Ditah F; Devaki P; Ditah C; Kamath PS; Charlton M
Hepatology; 2014 Sep; 60(3):815-22. PubMed ID: 24824965
[TBL] [Abstract][Full Text] [Related]
6. Variability in the performance characteristics of IgG anti-HEV assays and its impact on reliability of seroprevalence rates of hepatitis E.
Kodani M; Kamili NA; Tejada-Strop A; Poe A; Denniston MM; Drobeniuc J; Kamili S
J Med Virol; 2017 Jun; 89(6):1055-1061. PubMed ID: 27922197
[TBL] [Abstract][Full Text] [Related]
7. A Special Risk Group for Hepatitis E Infection: The First Record of North Cyprus.
Süer K; Güvenir M; Aykaç A
Pol J Microbiol; 2018; 67(4):525-528. PubMed ID: 30550239
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients.
Pas SD; Streefkerk RH; Pronk M; de Man RA; Beersma MF; Osterhaus AD; van der Eijk AA
J Clin Virol; 2013 Dec; 58(4):629-34. PubMed ID: 24210958
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis E Virus Seroprevalence and Associated Risk Factors in Pregnant Women Attending Antenatal Consultations in Senegal.
Diouara AAM; Lo S; Nguer CM; Senghor A; Diop Ndiaye H; Manga NM; Danfakha F; Diallo S; Faye Dieme ME; Thiam O; Biaye B; Manga NMP; Thiam F; Sarr H; Lo G; Ndour M; Manga SP; Diaby N; Dieng M; Diop I; Dieye Y; Toure Kane C; Peeters M; Ayouba A
Viruses; 2022 Aug; 14(8):. PubMed ID: 36016364
[TBL] [Abstract][Full Text] [Related]
10. Assessment of subclinical effects of Hepatitis E virus infection in the United States.
Anugwom C; Campbell C; Debes JD
J Viral Hepat; 2021 Jul; 28(7):1091-1097. PubMed ID: 33894038
[TBL] [Abstract][Full Text] [Related]
11. [Detection of anti-virus hepatitis e IgG and IgM antibodies using an automated method: experience of a university hospital].
Covarrubias N; Bohle C; Lara C; Miranda J; Hurtado C; Venegas M
Rev Chilena Infectol; 2021 Oct; 38(5):716-719. PubMed ID: 35506841
[TBL] [Abstract][Full Text] [Related]
12. Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates.
Wenzel JJ; Preiss J; Schemmerer M; Huber B; Jilg W
J Infect Dis; 2013 Feb; 207(3):497-500. PubMed ID: 23148290
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of hepatitis E infection among adults with concurrent chronic liver disease.
Wong RJ; Cheung R; Gish RG; Chitnis AS
J Viral Hepat; 2021 Nov; 28(11):1643-1655. PubMed ID: 34415657
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence and risk factors of hepatitis E virus infection in cancer patients in eastern China.
Bai MJ; Zhou N; Dong W; Li GX; Cong W; Zhu XQ
Int J Infect Dis; 2018 Jun; 71():42-47. PubMed ID: 29656134
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of Hepatitis E virus in children and adolescents living in urban Bogotá: An explorative cross-sectional study.
Fernández Villalobos NV; Kessel B; Torres Páez JC; Strömpl J; Kerrinnes T; de la Hoz Restrepo FP; Strengert M; Krause G
Front Public Health; 2023; 11():981172. PubMed ID: 36844812
[TBL] [Abstract][Full Text] [Related]
16. Anti-hepatitis E virus antibody prevalence in French expatriate workers.
Vernier M; Rossi-Tamisier M; Richet H; Brouqui P; Parola P; Bouamri Y; Colson P; Gautret P
Int J Infect Dis; 2013 Nov; 17(11):e1082-4. PubMed ID: 23953700
[TBL] [Abstract][Full Text] [Related]
17. Calibrating Hepatitis E Virus Serological Assays Using Asymptomatic Specimens Obtained in Japan.
Terahara K; Li TC; Matsubayashi K; Sakata H; Kato T; Naganuma A; Ogawa K; Honda K; Itakura J; Akutsu N; Tobita H; Korenaga M; Kanto T; Sugiyama R; Suzuki R; Hamaguchi I; Isogawa M; Takahashi Y
Microbiol Spectr; 2022 Oct; 10(5):e0214622. PubMed ID: 36125314
[TBL] [Abstract][Full Text] [Related]
18. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries.
Bendall R; Ellis V; Ijaz S; Ali R; Dalton H
J Med Virol; 2010 May; 82(5):799-805. PubMed ID: 20336757
[TBL] [Abstract][Full Text] [Related]
19. Performance of Hepatitis E Virus (HEV)-antibody tests: a comparative analysis based on samples from individuals with direct contact to domestic pigs or wild boar in Germany.
Sommerkorn FM; Schauer B; Schreiner T; Fickenscher H; Krumbholz A
Med Microbiol Immunol; 2017 Jun; 206(3):277-286. PubMed ID: 28397024
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hepatitis E virus seroprevalence between HBsAg-positive population and healthy controls in Shandong province, China.
Zhang L; Jiang Z; Lv J; Liu J; Yan B; Feng Y; Li L; Zhang G; Wang F; Xu A
BMC Infect Dis; 2018 Feb; 18(1):75. PubMed ID: 29433428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
